How to contact the center
HCP Center
Patients are taken care of by a dedicated multidisciplinary team that welcomes and guides them in the treatment process, including ophthalmologists, orthoptists and nurses specialized in diagnostic and rehabilitative techniques, counselors and guidance and mobility operators to complete the qualification/rehabilitation course, as well as paediatricians, audiologists, neurologists, nephrologists for the diagnosis and treatment of syndromic forms.
To book the first diagnostic day hospital, call the Rare Eye Disease Center at the telephone number: 081 566 67 62 (every Tuesday and Thursday from 11.00 to 13.00).
To book subsequent visits on an outpatient basis (follow-up), contact the company CUP at the telephone number: 800 177 780, indicating the name of your pathology.
Picture : Falk2, via Wikimedia Commons
Contact
AOU Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
Team
Pr Francesca Simonelli
Italy
Pr Francesco Testa
Italy
Dr Valentina Di Iorio
Italy
Dr Raffaella Brunetti Pierri
Italy
Clinical trials
An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects G (p.Cys998X) Mutation.
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Clinical and Molecular Studies in Families With Inherited Eye Disease
Natural history of patients with inherited retinal diseases due to mutations in RPE65 gene
Safety and Efficacy of Emixustat in Stargardt Disease.
Natural History Study in Subjects With Usher Syndrome.
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
A Multicenter, Prospective, Longitudinal, Observational Study in Children and Adults With Stargardt Disease Related Atrophy Secondary to Biallelic Mutations in the ABCA4 Gene